Difference between revisions of "Template:Hormone levels with medroxyprogesterone acetate"
Jump to navigation
Jump to search
Template documentation
imported>Medgirl131 |
imported>Mikeblas (remove unused reference name to avoid duplication at transclusion) |
||
| Line 5: | Line 5: | ||
| style="font-size:small;" | | style="font-size:small;" | ||
| − | | File:Levels of medroxyprogesterone acetate with 2.5 or 5 mg per day oral medroxyprogesterone acetate in postmenopausal women.png | MPA levels with 2.5 or 5 mg/day [[oral administration|oral]] MPA in combination with 1 or 2 mg/day [[estradiol valerate]] ([[Indivina]]) in postmenopausal women.<ref | + | | File:Levels of medroxyprogesterone acetate with 2.5 or 5 mg per day oral medroxyprogesterone acetate in postmenopausal women.png | MPA levels with 2.5 or 5 mg/day [[oral administration|oral]] MPA in combination with 1 or 2 mg/day [[estradiol valerate]] ([[Indivina]]) in postmenopausal women.<ref>{{cite journal|last1=Järvinen|first1=Asko|last2=Kainulainen|first2=Petri|last3=Nissilä|first3=Minna|last4=Nikkanen|first4=Hanna|last5=Kela|first5=Marjo|title=Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women|journal=Maturitas|volume=47|issue=3|year=2004|pages=209–217|issn=03785122|doi=10.1016/j.maturitas.2003.01.001}}</ref> |
| File:Medroxyprogesterone acetate levels after a single 150 mg intramuscular injection of medroxyprogesterone acetate in women.png | MPA levels after a single 150 mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986">{{cite book|last1=Goebelsmann|first1=Uwe|chapter=Pharmacokinetics of Contraceptive Steroids in Humans|editor1=A. T. Gregoire|editor2=Richard P. Blye|title=Contraceptive Steroids: Pharmacology and Safety|chapter-url=https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67|date=1986|publisher=Springer Science & Business Media|isbn=978-1-4613-2241-2|pages=67–111|doi=10.1007/978-1-4613-2241-2_4}}</ref><ref name="pmid833262">{{cite journal | vauthors = Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR | title = Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA | journal = J. Clin. Endocrinol. Metab. | volume = 44 | issue = 1 | pages = 32–8 | date = January 1977 | pmid = 833262 | doi = 10.1210/jcem-44-1-32 | url = }}</ref> | | File:Medroxyprogesterone acetate levels after a single 150 mg intramuscular injection of medroxyprogesterone acetate in women.png | MPA levels after a single 150 mg [[intramuscular injection]] of MPA (Depo-Provera) in [[aqueous suspension]] in women.<ref name="Goebelsmann1986">{{cite book|last1=Goebelsmann|first1=Uwe|chapter=Pharmacokinetics of Contraceptive Steroids in Humans|editor1=A. T. Gregoire|editor2=Richard P. Blye|title=Contraceptive Steroids: Pharmacology and Safety|chapter-url=https://books.google.com/books?id=7dnTBwAAQBAJ&pg=PA67|date=1986|publisher=Springer Science & Business Media|isbn=978-1-4613-2241-2|pages=67–111|doi=10.1007/978-1-4613-2241-2_4}}</ref><ref name="pmid833262">{{cite journal | vauthors = Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR | title = Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA | journal = J. Clin. Endocrinol. Metab. | volume = 44 | issue = 1 | pages = 32–8 | date = January 1977 | pmid = 833262 | doi = 10.1210/jcem-44-1-32 | url = }}</ref> | ||
Revision as of 14:19, 23 March 2020
- Hormone levels with medroxyprogesterone acetate
MPA levels with 2.5 or 5 mg/day oral MPA in combination with 1 or 2 mg/day estradiol valerate (Indivina) in postmenopausal women.[1]
MPA levels after a single 150 mg intramuscular injection of MPA (Depo-Provera) in aqueous suspension in women.[2][3]
MPA levels after a single 25 to 150 mg intramuscular injection of MPA (Depo-Provera) in aqueous suspension in women.[2][4]
MPA levels after a single 104 mg subcutaneous injection of MPA (Depo-SubQ Provera) in aqueous suspension in women.[5]
See also
References
- ↑ Järvinen, Asko; Kainulainen, Petri; Nissilä, Minna; Nikkanen, Hanna; Kela, Marjo (2004). "Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women". Maturitas. 47 (3): 209–217. doi:10.1016/j.maturitas.2003.01.001. ISSN 0378-5122.
- ↑ 2.0 2.1 Goebelsmann, Uwe (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In A. T. Gregoire; Richard P. Blye (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
- ↑ Ortiz A, Hirol M, Stanczyk FZ, Goebelsmann U, Mishell DR (January 1977). "Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA". J. Clin. Endocrinol. Metab. 44 (1): 32–8. doi:10.1210/jcem-44-1-32. PMID 833262.
- ↑ Fotherby K, Koetsawang S, Mathrubutham M (November 1980). "Pharmacokinetic study of different doses of Depo Provera". Contraception. 22 (5): 527–36. doi:10.1016/0010-7824(80)90105-5. PMID 6451351.
- ↑ "depo-subQ Provera" (PDF). FDA. 2017. Retrieved 31 March 2018.
| Editors can experiment in this template's sandbox (create | mirror) and testcases (create) pages. Subpages of this template. |



